NO20063221L - Fremgangsmate for behandling av matinntak - Google Patents
Fremgangsmate for behandling av matinntakInfo
- Publication number
- NO20063221L NO20063221L NO20063221A NO20063221A NO20063221L NO 20063221 L NO20063221 L NO 20063221L NO 20063221 A NO20063221 A NO 20063221A NO 20063221 A NO20063221 A NO 20063221A NO 20063221 L NO20063221 L NO 20063221L
- Authority
- NO
- Norway
- Prior art keywords
- person
- food intake
- eating
- procedure
- obesity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL16159504A IL161595A0 (en) | 2004-04-22 | 2004-04-22 | Betahistine as a weight management agent |
US67029005P | 2005-04-12 | 2005-04-12 | |
PCT/IL2005/000440 WO2005101979A2 (en) | 2004-04-22 | 2005-04-21 | Method of food intake management |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20063221L true NO20063221L (no) | 2006-10-06 |
Family
ID=35197421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20063221A NO20063221L (no) | 2004-04-22 | 2006-07-11 | Fremgangsmate for behandling av matinntak |
Country Status (10)
Country | Link |
---|---|
US (5) | US7737165B2 (ko) |
EP (1) | EP1737454A4 (ko) |
JP (1) | JP2007533733A (ko) |
KR (1) | KR20060134041A (ko) |
BR (1) | BRPI0506807A (ko) |
CA (1) | CA2553309A1 (ko) |
EA (1) | EA200601414A1 (ko) |
IL (1) | IL176793A0 (ko) |
NO (1) | NO20063221L (ko) |
WO (1) | WO2005101979A2 (ko) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
US20080051440A1 (en) * | 2004-04-22 | 2008-02-28 | Mor Research Applications Ltd. | Compositions for weight management |
BRPI0506807A (pt) * | 2004-04-22 | 2007-05-29 | Mor Research Applic Ltd | método de gerenciamento de consumo de alimento e composição farmacológica |
WO2007020079A2 (en) * | 2005-08-17 | 2007-02-22 | Synthon B.V. | Orally disintegratable simvastatin tablets |
US8242148B2 (en) * | 2005-12-23 | 2012-08-14 | Nelson Erik B | Treatment methods employing histamine H3 receptor antagonists, including betahistine |
UA98938C2 (ru) * | 2006-06-16 | 2012-07-10 | Теракос, Инк. | Лечение психологических состояний с применением антагонистов мускариновых рецепторов м1 |
US8748419B2 (en) * | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
US20080033019A1 (en) * | 2006-08-07 | 2008-02-07 | Duke University | Cholesterol lowering drug combination |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
CN105250285B (zh) * | 2007-04-11 | 2019-09-06 | 奥默罗斯公司 | 预防和治疗成瘾的组合物和方法 |
WO2008157094A1 (en) * | 2007-06-13 | 2008-12-24 | Cypress Bioscience, Inc. | Improving the tolerability of mirtazapine and a second active by using them in combination |
JP5513378B2 (ja) * | 2007-06-15 | 2014-06-04 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイテッド | 治療化合物 |
BRPI0912126A2 (pt) | 2008-05-27 | 2015-11-03 | Univ Melbourne | método de tratamento de mamíferos com disfunções na trompa de eustáquio |
US20120115778A1 (en) * | 2009-07-15 | 2012-05-10 | The Trustees Of Columbia University In The City Of New York | Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2 |
US20110021507A1 (en) * | 2009-07-22 | 2011-01-27 | Theracos, Inc. | Inhibiting antipsychotic-induced weight gain |
CA2777332A1 (en) * | 2009-10-13 | 2011-04-21 | Nestec S.A. | Systems for evaluating dietary intake and methods of using same |
EP2506712B8 (en) | 2009-12-04 | 2019-06-19 | Alkermes Pharma Ireland Limited | Morphinan derivatives for the treatment of drug overdose |
US20110143704A1 (en) | 2009-12-14 | 2011-06-16 | William Lorentz | Specialized dial a chip |
SI2608670T1 (sl) | 2010-08-23 | 2019-04-30 | Alkermes Pharma Ireland Limited | Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil |
US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
US20140072935A1 (en) * | 2012-09-07 | 2014-03-13 | Tina M. Herron | Method of Regulating Caloric Intake |
AU2014268361B2 (en) | 2013-05-24 | 2018-09-06 | Alkermes Pharma Ireland Limited | Morphan and morphinan analogues, and methods of use |
EP3003311A2 (en) | 2013-05-24 | 2016-04-13 | Alkermes Pharma Ireland Limited | Methods for treating depressive symptoms |
RU2540911C2 (ru) * | 2013-06-11 | 2015-02-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ коррекции синдрома ночной еды у пациентов с тревожно-депрессивными расстройствами |
DE102015202695A1 (de) * | 2015-02-13 | 2016-08-18 | Carl Zeiss Smt Gmbh | Prüfvorrichtung sowie Verfahren zum Prüfen eines Spiegels |
BR112019015687A2 (pt) | 2017-02-02 | 2020-04-28 | Otolanum Ag | composição intranasal compreendendo beta-histina |
EP4243768A1 (en) | 2020-11-12 | 2023-09-20 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1577871A (en) * | 1976-05-28 | 1980-10-29 | Unimed Inc | Prevention of myocardial infarction |
JPS55154915A (en) * | 1979-05-21 | 1980-12-02 | Jiyan Sadeia Shieruki | Medicine mold |
US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
IL143944A0 (en) | 1998-12-23 | 2002-04-21 | Searle Llc | Combinations for cardiovascular indications |
CN1155579C (zh) * | 1998-12-23 | 2004-06-30 | 马克西姆药品公司 | 二盐酸组胺的合成 |
IT1309591B1 (it) | 1999-03-05 | 2002-01-24 | Formenti Farmaceutici Spa | Composizioni a rilascio controllato di betaistina. |
WO2000071106A2 (en) * | 1999-05-19 | 2000-11-30 | Astrazeneca Ab | Method of treating weight gain |
PL202935B1 (pl) * | 2000-03-08 | 2009-08-31 | Awd Pharma Gmbh & Co Kg | Doustny preparat farmaceutyczny o zmiennie nastawianej charakterystyce uwalniania oraz sposób wytwarzania takiego preparatu |
US6607748B1 (en) * | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
AU2002320025A1 (en) | 2001-04-11 | 2002-11-11 | Atherogenics, Inc. | Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality |
US20030162824A1 (en) | 2001-11-12 | 2003-08-28 | Krul Elaine S. | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor |
US20040110803A1 (en) | 2002-09-13 | 2004-06-10 | Hossein Dovlatabadi | Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels |
US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
BRPI0506807A (pt) * | 2004-04-22 | 2007-05-29 | Mor Research Applic Ltd | método de gerenciamento de consumo de alimento e composição farmacológica |
US20080051440A1 (en) * | 2004-04-22 | 2008-02-28 | Mor Research Applications Ltd. | Compositions for weight management |
US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
WO2006023702A2 (en) | 2004-08-20 | 2006-03-02 | Cypress Bioscience, Inc. | Method for treating sleep related breathing disorders with setiptiline |
-
2005
- 2005-04-21 BR BRPI0506807-0A patent/BRPI0506807A/pt not_active IP Right Cessation
- 2005-04-21 JP JP2007509061A patent/JP2007533733A/ja active Pending
- 2005-04-21 KR KR1020067015532A patent/KR20060134041A/ko not_active Application Discontinuation
- 2005-04-21 EA EA200601414A patent/EA200601414A1/ru unknown
- 2005-04-21 WO PCT/IL2005/000440 patent/WO2005101979A2/en not_active Application Discontinuation
- 2005-04-21 CA CA002553309A patent/CA2553309A1/en not_active Abandoned
- 2005-04-21 EP EP05734836A patent/EP1737454A4/en not_active Withdrawn
- 2005-11-22 US US11/283,928 patent/US7737165B2/en active Active
- 2005-11-22 US US11/283,865 patent/US20060084686A1/en not_active Abandoned
-
2006
- 2006-07-11 IL IL176793A patent/IL176793A0/en unknown
- 2006-07-11 NO NO20063221A patent/NO20063221L/no not_active Application Discontinuation
-
2007
- 2007-08-03 US US11/882,740 patent/US20080004322A1/en not_active Abandoned
- 2007-08-03 US US11/882,678 patent/US20080051439A1/en not_active Abandoned
- 2007-08-03 US US11/882,677 patent/US20080004324A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1737454A4 (en) | 2007-08-08 |
WO2005101979A3 (en) | 2006-07-27 |
BRPI0506807A (pt) | 2007-05-29 |
US7737165B2 (en) | 2010-06-15 |
EP1737454A2 (en) | 2007-01-03 |
EA200601414A1 (ru) | 2007-02-27 |
US20080004324A1 (en) | 2008-01-03 |
IL176793A0 (en) | 2006-10-31 |
US20080004322A1 (en) | 2008-01-03 |
KR20060134041A (ko) | 2006-12-27 |
US20060084686A1 (en) | 2006-04-20 |
US20060073217A1 (en) | 2006-04-06 |
CA2553309A1 (en) | 2005-11-03 |
US20080051439A1 (en) | 2008-02-28 |
JP2007533733A (ja) | 2007-11-22 |
WO2005101979A2 (en) | 2005-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20063221L (no) | Fremgangsmate for behandling av matinntak | |
WO2006105345A3 (en) | Compositions and methods for the control, prevention, and treatment of obesity and eating disorders | |
WO2007112069A3 (en) | Endothelin and endothelin receptor agonists in the treatment of metabolic diseases | |
EP1841781A4 (en) | USE OF IL-22 FOR THE TREATMENT OF METABOLISM DISORDER | |
WO2006129193A3 (en) | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss | |
KHAJAVI et al. | The Effect of | |
GB2441276A (en) | Multiple media access control apparatus and method | |
WO2004110385A3 (en) | Modulators of the glucocorticoid receptor and method | |
WO2006091505A3 (en) | Neuropeptide y receptor agonists | |
KR20200051431A (ko) | 의자가 돌아가는 일체형 책걸상 | |
RU2003130720A (ru) | Способ коррекции нарушений адаптации у больных синдромом хронической усталости | |
Esler | On a low calorie diet, are there separate and discrete effects of negative energy balance and weight loss on blood pressure? | |
Bitok et al. | Does a daily walnut supplement given for a year result in body weight gain? | |
Dubey et al. | Epigenetic regulation of autophagy by histone deacetylases in retinal pigment epithelium | |
Aguirre‐Fuerte et al. | ALTERATIONS IN THE ENDOCANNABINOID SYSTEM IN ASTROCYTES RELATED TO COMMERCIAL SWEETENER INTAKE | |
Kunkel et al. | Effects of Heat Therapy on Prostate Cancer Cells Subjected to 4 Gy Radiation | |
Yamada et al. | Body weight reduction by exercise is more effective than by dietary restriction even when dietary condition is equal except for energy | |
Kolev et al. | Balance exercises and physical therapy management of vestibular dysfunction–our experience | |
Guydish et al. | Predictors of retention among drug users in day treatment | |
Rollins et al. | Blood pressure responses to hindlimb arterial bradykinin injection are mediated by bradykinin 2 receptors in decerebrate rats | |
McClellan et al. | HMGB1 antagonist, Box A reduces severity of Pseudomonas keratitis in susceptible C57BL/6 mice. | |
Chai et al. | Role of Dlx5 in the development of the palatal‐pharyngeal region in higher vertebrates | |
Moubayed et al. | Thromboembolism in Rhinoplasty. Aesthet Surg J 2017; 37 (3): NP34-NP35. DOI: 10.1093/asj/sjw252 | |
KR20200081726A (ko) | Pc방용 음식 받침대 | |
Akamatsu et al. | Anatomical substract of the masseter muscle myofascial trigger points |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |